Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RARE |
---|---|---|
09:32 ET | 4579 | 52.09 |
09:34 ET | 24900 | 51.745 |
09:36 ET | 100 | 51.745 |
09:38 ET | 500 | 51.59 |
09:39 ET | 100 | 51.7 |
09:41 ET | 1019 | 51.79 |
09:45 ET | 100 | 51.945 |
09:48 ET | 100 | 51.945 |
09:50 ET | 242 | 51.965 |
09:54 ET | 1711 | 51.66 |
09:56 ET | 319 | 51.505 |
09:57 ET | 1954 | 51.395 |
09:59 ET | 25102 | 51.49 |
10:01 ET | 1278 | 51.425 |
10:03 ET | 733 | 51.425 |
10:06 ET | 100 | 51.515 |
10:08 ET | 990 | 51.3474 |
10:10 ET | 100 | 51.32 |
10:12 ET | 1300 | 51.45 |
10:14 ET | 1400 | 51.33 |
10:15 ET | 200 | 51.41 |
10:17 ET | 300 | 51.43 |
10:19 ET | 700 | 51.58 |
10:24 ET | 412 | 51.67 |
10:26 ET | 100 | 51.75 |
10:28 ET | 1200 | 51.82 |
10:30 ET | 8501 | 51.57 |
10:32 ET | 200 | 51.665 |
10:33 ET | 200 | 51.625 |
10:35 ET | 798 | 51.48 |
10:37 ET | 100 | 51.5 |
10:39 ET | 1534 | 51.54 |
10:42 ET | 317 | 51.47 |
10:46 ET | 100 | 51.46 |
10:48 ET | 200 | 51.455 |
10:50 ET | 400 | 51.28 |
10:51 ET | 500 | 51.29 |
10:53 ET | 500 | 51.34 |
10:55 ET | 5546 | 51.26 |
10:57 ET | 500 | 51.22 |
11:00 ET | 100 | 51.2325 |
11:02 ET | 1670 | 51.1 |
11:04 ET | 7297 | 51.02 |
11:06 ET | 4715 | 50.945 |
11:08 ET | 1656 | 50.91 |
11:09 ET | 500 | 50.93 |
11:11 ET | 2507 | 51.005 |
11:13 ET | 291 | 51.015 |
11:15 ET | 410 | 51 |
11:20 ET | 1605 | 50.96 |
11:22 ET | 2221 | 51 |
11:24 ET | 707 | 51.06 |
11:26 ET | 10625 | 50.94 |
11:27 ET | 600 | 50.88 |
11:29 ET | 200 | 50.885 |
11:31 ET | 800 | 50.92 |
11:33 ET | 400 | 50.91 |
11:36 ET | 783 | 51 |
11:38 ET | 3391 | 51.03 |
11:40 ET | 33313 | 50.995 |
11:42 ET | 3248 | 50.97 |
11:44 ET | 5120 | 51 |
11:45 ET | 5164 | 50.96 |
11:47 ET | 300 | 50.99 |
11:49 ET | 5487 | 50.97 |
11:51 ET | 3624 | 51.04 |
11:54 ET | 1500 | 51.06 |
11:56 ET | 903 | 51.14 |
11:58 ET | 2543 | 51.0677 |
12:00 ET | 600 | 50.99 |
12:02 ET | 200 | 51.01 |
12:03 ET | 700 | 51.065 |
12:05 ET | 200 | 51.085 |
12:07 ET | 2432 | 51.01 |
12:09 ET | 200 | 51.04 |
12:12 ET | 488 | 51.08 |
12:14 ET | 2594 | 51.105 |
12:16 ET | 1527 | 51.03 |
12:18 ET | 6089 | 51.15 |
12:20 ET | 1780 | 51.18 |
12:21 ET | 2163 | 51.185 |
12:23 ET | 205 | 51.25 |
12:25 ET | 1537 | 51.25 |
12:27 ET | 200 | 51.224 |
12:30 ET | 4300 | 51.27 |
12:32 ET | 730 | 51.28 |
12:34 ET | 200 | 51.25 |
12:36 ET | 4614 | 51.07 |
12:38 ET | 1211 | 51.08 |
12:39 ET | 7367 | 51.04 |
12:41 ET | 10307 | 50.97 |
12:45 ET | 688 | 50.995 |
12:48 ET | 292 | 50.95 |
12:50 ET | 700 | 50.935 |
12:52 ET | 931 | 50.935 |
12:54 ET | 100 | 50.935 |
12:56 ET | 364 | 50.97 |
12:57 ET | 100 | 50.97 |
12:59 ET | 300 | 50.97 |
01:01 ET | 249 | 50.97 |
01:03 ET | 1551 | 51.065 |
01:06 ET | 200 | 51.13 |
01:08 ET | 200 | 51.105 |
01:10 ET | 3132 | 50.97 |
01:12 ET | 200 | 51.07 |
01:14 ET | 100 | 51.04 |
01:15 ET | 1015 | 50.97 |
01:17 ET | 1757 | 50.99 |
01:19 ET | 498 | 51.01 |
01:21 ET | 7300 | 51.015 |
01:24 ET | 3015 | 50.975 |
01:26 ET | 1300 | 51 |
01:28 ET | 832 | 51.01 |
01:30 ET | 2584 | 51.04 |
01:32 ET | 200 | 51.02 |
01:33 ET | 4793 | 50.955 |
01:35 ET | 700 | 50.985 |
01:37 ET | 322 | 50.95 |
01:39 ET | 100 | 50.94 |
01:42 ET | 803 | 50.895 |
01:44 ET | 100 | 50.905 |
01:46 ET | 100 | 50.88 |
01:48 ET | 3177 | 50.88 |
01:50 ET | 500 | 50.89 |
01:51 ET | 751 | 50.89 |
01:53 ET | 1799 | 50.89 |
01:55 ET | 1488 | 50.86 |
01:57 ET | 1107 | 50.895 |
02:00 ET | 1127 | 50.895 |
02:02 ET | 3791 | 50.98 |
02:04 ET | 400 | 51.01 |
02:06 ET | 2520 | 50.935 |
02:08 ET | 400 | 50.975 |
02:09 ET | 6413 | 51.045 |
02:11 ET | 500 | 51.06 |
02:13 ET | 1351 | 50.96 |
02:18 ET | 1116 | 50.91 |
02:20 ET | 515 | 50.83 |
02:22 ET | 2600 | 50.94 |
02:24 ET | 2140 | 50.9 |
02:26 ET | 300 | 50.91 |
02:27 ET | 300 | 50.905 |
02:29 ET | 2500 | 50.92 |
02:31 ET | 2740 | 50.92 |
02:33 ET | 800 | 50.95 |
02:36 ET | 4091 | 50.87 |
02:38 ET | 600 | 50.85 |
02:40 ET | 808 | 50.86 |
02:42 ET | 500 | 50.82 |
02:44 ET | 600 | 50.76 |
02:45 ET | 4139 | 50.8 |
02:47 ET | 518 | 50.76 |
02:49 ET | 3198 | 50.8 |
02:51 ET | 800 | 50.79 |
02:54 ET | 1200 | 50.81 |
02:56 ET | 2665 | 50.825 |
02:58 ET | 300 | 50.83 |
03:00 ET | 4854 | 50.775 |
03:02 ET | 3185 | 50.855 |
03:03 ET | 1336 | 50.855 |
03:05 ET | 3598 | 50.805 |
03:07 ET | 10735 | 50.89 |
03:09 ET | 11930 | 50.9573 |
03:12 ET | 1120 | 51.05 |
03:14 ET | 2576 | 51.04 |
03:16 ET | 1300 | 51.03 |
03:18 ET | 6793 | 50.975 |
03:20 ET | 4200 | 50.985 |
03:21 ET | 2053 | 51.01 |
03:23 ET | 2122 | 50.9 |
03:25 ET | 2028 | 50.83 |
03:27 ET | 400 | 50.84 |
03:30 ET | 3504 | 50.895 |
03:32 ET | 2704 | 50.86 |
03:34 ET | 500 | 50.85 |
03:36 ET | 3058 | 50.85 |
03:38 ET | 2501 | 50.8236 |
03:39 ET | 700 | 50.865 |
03:41 ET | 3803 | 50.835 |
03:43 ET | 2821 | 50.84 |
03:45 ET | 4999 | 50.96 |
03:48 ET | 3587 | 50.99 |
03:50 ET | 2040 | 51.03 |
03:52 ET | 7597 | 51.175 |
03:54 ET | 6573 | 51.105 |
03:56 ET | 10276 | 51.1 |
03:57 ET | 12119 | 51.09 |
03:59 ET | 127465 | 50.99 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ultragenyx Pharmaceutical Inc | 4.8B | -7.0x | --- |
CRISPR Therapeutics AG | 4.1B | -14.5x | --- |
Axsome Therapeutics Inc | 4.3B | -13.7x | --- |
Amicus Therapeutics Inc | 3.4B | -28.8x | --- |
Denali Therapeutics Inc | 3.8B | -9.1x | --- |
Apellis Pharmaceuticals Inc | 3.4B | -9.9x | --- |
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.8B |
---|---|
Revenue (TTM) | $481.3M |
Shares Outstanding | 92.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $-7.29 |
Book Value | $3.35 |
P/E Ratio | -7.0x |
Price/Sales (TTM) | 9.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -114.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.